Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Cancels Part B Demo Before HHS Secretary-Designate Price Does

Executive Summary

President-elect Trump’s selection for HHS secretary, Rep. Tom Price, R-Ga., has been an outspoken critic of the proposed Medicare Part B drug demonstration project.

Advertisement

Related Content

Drug Payment Experiments Coming To Medicare, Medicaid
Policy People In The News: Patrick Conway Departs CMS
Part B Reforms: MedPAC Moving Forward With 'Drug Value Program' Proposal
Sweeping FDA Changes Could Have “Disastrous Consequences” For Biotech Investment
HHS Nominee Price Sidesteps Medicare Drug Pricing Negotiation Questions
The Trump Administration: Seven More Things To Watch Out For
Trump’s HHS, CMS Leadership Choices Underscore Focus On ACA Reform
Part B Demo Comments Overwhelmingly Negative, Uniform In Content
Medicare Payment Demo Would Put Often-Prescribed Cancer Drugs ‘Underwater’

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

PS119693

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel